Онкопедиатрия. 2014; 1: 11-16
Поздняя нейротоксичность противоопухолевого лечения у детей: часть 1
Аннотация
Комплексный подход играет важную роль при лечении злокачественных опухолей у детей. Тем не менее, эта терапия может привести к различным отдаленным последствиям, включая нейротоксичность. Клиническая практика нередко демонстрирует возникновение периферических и центральных нейропатий. Их патофизиология не совсем понятна. Недавние исследования показали, что нейропатии обладают гетерогенностью, особенно в анатомической локализации, а также в клинической, электрофизиологической и нейровизуализационной симптоматике. В статье представлен обзор исследований по поздней нейротоксичности, возникающей после химиотерапии, хирургического и лучевого лечения.
Список литературы
1. Скоромец А.А., Скоромец Т.А. Топическая диагностика заболеваний нервной системы. СПб.: Из-во «Политехника». 2002. 399 с.
2. Postma T.J., Heimans J.J. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000; 11: 509–13.
3. Pal P.K. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyog Clin Neurophysiol. 1999; 39: 323–30.
4. Moudgil S.S., Riggs J.E. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000; 34: 1136–8.
5. Jeng M.R., Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001; 18: 137–42.
6. Molloy F.M., Floeter M.K., Syed N.A., Sandbrink F., Culcea E., Steinberg S.M., Dahut W., Pluda J., Kruger E.A., Reed E., Figg W.D. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001; 24: 1050–7.
7. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am J Med. 2000; 108: 487–95.
8. Hartmann J.T., Kollmannsberger C., Kanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999; 83: 866–9.
9. Planting A.S.T., Catimel G., deMulder P.H.M., de Graeff A., Höppener F., Verweij J., Oster W., Vermorken J.B. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol. 1999; 10: 693–700.
10. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol. 2001; 127: 55–8.
11. Hilkens P.H.E., Pronk L.C., Verweij J., Vecht C.J., van Putten W.L., van den Bent M.J. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997; 75: 417–22.
12. Fazio R., Quattrini A., Bolognesi A. Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol. 1999; 98: 651–3.
13. Cerny T., Küpfer A. The enigma of ifosfamide encephalopathy. Ann Oncol. 1992; 3: 679–81.
14. Berg S.L., Blaney S.M., Devidas M., Lampkin T.A., Murgo A., Bernstein M., Billett A., Kurtzberg J., Reaman G., Gaynon P., Whitlock J., Krailo M., Harris M.B. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23 (15): 3376–82.
15. Zimmerman R.D., Fleming C.A., Lee B.C.P., Saint-Louis L.A., Deck M.D. Periventricular hyperintensity as seen by magnetic resonance: prevalence and significance. Am J Neuroradiol. 1986; 7: 13–20.
16. Constine L.S., Konski A., Ekholm S., McDonald S., Rubin P. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys. 1988; 15: 319– 30.
17. Duffner P.K., Cohen M.E., Berger P., Parthasarathy K.L., Bakshi S., Ettinger L.J., Freeman A. Abnormalities of CT scans and altered methotrexate clearance in children with central nervous system leukemia. Ann Neurol. 1981; 10: 286–287.
18. Mahoney D., Shuster J., Nitschke R. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy. A Pediatric Oncology Group Study. J Clin Oncol. 1998; 16: 1712–22.
19. Bitzer M., Topka H. Progressive cerebral occlusive disease after radiation therapy. Stroke. 1995; 26: 131–6.
20. Jensen F.K., Wagner A. Intracranial aneurysm following radiation therapy for medulloblastoma. Acta Radiol. 1997; 38: 37–42.
21. Tandon N., Vollmer D.G., New P.Z., Hevezi J.M., Herman T., Kagan-Hallet K., West G.A. Fulminant radiation-induced necrosis after stereotactic radiation therapy to the posterior fossa. J Neurosurg. 2001; 95: 507–12.
22. Marks J.E., Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. Prog Exp Tumor Res. 1985; 29: 210–8.
23. Kumar A.J., Leeds N.E., Fuller G.N. Malignant gliomas: MR imaging spectrum of radiation therapy – and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000; 217: 377–84.
24. Chin L.S., DiBiase S. Radiation following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow-up. J Neurosurg. 2001; 94: 899–904.
25. Liu C.Y., Yim B.T., Wozniak A.J. Anticoagulation therapy for radiationinduced myelopathy. Ann Pharmacother. 2001; 35: 188–91.
26. Rampling R., Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998; 11: 627–32.
27. Dunton S.F., Nitschke R., Spruce W.E., Bodensteiner J., Krous H.F. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine-arabinoside. A Pediatric Oncology Group Study. Cancer. 1986; 57: 1083–8.
28. Watterson J., Toogood I., Nieder M., Morse M., Frierdich S., Lee Y., Moertel C.L., Priest J.R. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer. 1994; 74: 3034–41.
29. Oeffinger K.C. Longitudinal risk-based health care for adult survivors of childhood cancer. Current. Probl. Cancer. 2003; 27: 143–67.
Oncopediatrics. 2014; 1: 11-16
Tardive Neurotoxicity of Antineoplastic Therapy in Children: Part 1
Abstract
Combined modality therapy plays an important role in childhood cancer managements. Nonetheless, the treatment can lead to a different late long-term consequences, including neurotoxicity. Clinical practice demonstrates the occurrence of peripheral and central neuropathies. The physiopathology is still under study. Recent reports demonstrate that neuropathies show more heterogeneity, particularly in the anatomic sites, occuring in the clinical, electrophysiological, and neuroimaging features. The article presents an overview of tardive neurotoxicity occuring after chemotherapy, surgery, and irradiation.
References
1. Skoromets A.A., Skoromets T.A. Topicheskaya diagnostika zabolevanii nervnoi sistemy. SPb.: Iz-vo «Politekhnika». 2002. 399 s.
2. Postma T.J., Heimans J.J. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000; 11: 509–13.
3. Pal P.K. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyog Clin Neurophysiol. 1999; 39: 323–30.
4. Moudgil S.S., Riggs J.E. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000; 34: 1136–8.
5. Jeng M.R., Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001; 18: 137–42.
6. Molloy F.M., Floeter M.K., Syed N.A., Sandbrink F., Culcea E., Steinberg S.M., Dahut W., Pluda J., Kruger E.A., Reed E., Figg W.D. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001; 24: 1050–7.
7. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am J Med. 2000; 108: 487–95.
8. Hartmann J.T., Kollmannsberger C., Kanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999; 83: 866–9.
9. Planting A.S.T., Catimel G., deMulder P.H.M., de Graeff A., Höppener F., Verweij J., Oster W., Vermorken J.B. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol. 1999; 10: 693–700.
10. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol. 2001; 127: 55–8.
11. Hilkens P.H.E., Pronk L.C., Verweij J., Vecht C.J., van Putten W.L., van den Bent M.J. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997; 75: 417–22.
12. Fazio R., Quattrini A., Bolognesi A. Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol. 1999; 98: 651–3.
13. Cerny T., Küpfer A. The enigma of ifosfamide encephalopathy. Ann Oncol. 1992; 3: 679–81.
14. Berg S.L., Blaney S.M., Devidas M., Lampkin T.A., Murgo A., Bernstein M., Billett A., Kurtzberg J., Reaman G., Gaynon P., Whitlock J., Krailo M., Harris M.B. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23 (15): 3376–82.
15. Zimmerman R.D., Fleming C.A., Lee B.C.P., Saint-Louis L.A., Deck M.D. Periventricular hyperintensity as seen by magnetic resonance: prevalence and significance. Am J Neuroradiol. 1986; 7: 13–20.
16. Constine L.S., Konski A., Ekholm S., McDonald S., Rubin P. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys. 1988; 15: 319– 30.
17. Duffner P.K., Cohen M.E., Berger P., Parthasarathy K.L., Bakshi S., Ettinger L.J., Freeman A. Abnormalities of CT scans and altered methotrexate clearance in children with central nervous system leukemia. Ann Neurol. 1981; 10: 286–287.
18. Mahoney D., Shuster J., Nitschke R. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy. A Pediatric Oncology Group Study. J Clin Oncol. 1998; 16: 1712–22.
19. Bitzer M., Topka H. Progressive cerebral occlusive disease after radiation therapy. Stroke. 1995; 26: 131–6.
20. Jensen F.K., Wagner A. Intracranial aneurysm following radiation therapy for medulloblastoma. Acta Radiol. 1997; 38: 37–42.
21. Tandon N., Vollmer D.G., New P.Z., Hevezi J.M., Herman T., Kagan-Hallet K., West G.A. Fulminant radiation-induced necrosis after stereotactic radiation therapy to the posterior fossa. J Neurosurg. 2001; 95: 507–12.
22. Marks J.E., Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. Prog Exp Tumor Res. 1985; 29: 210–8.
23. Kumar A.J., Leeds N.E., Fuller G.N. Malignant gliomas: MR imaging spectrum of radiation therapy – and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000; 217: 377–84.
24. Chin L.S., DiBiase S. Radiation following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow-up. J Neurosurg. 2001; 94: 899–904.
25. Liu C.Y., Yim B.T., Wozniak A.J. Anticoagulation therapy for radiationinduced myelopathy. Ann Pharmacother. 2001; 35: 188–91.
26. Rampling R., Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998; 11: 627–32.
27. Dunton S.F., Nitschke R., Spruce W.E., Bodensteiner J., Krous H.F. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine-arabinoside. A Pediatric Oncology Group Study. Cancer. 1986; 57: 1083–8.
28. Watterson J., Toogood I., Nieder M., Morse M., Frierdich S., Lee Y., Moertel C.L., Priest J.R. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer. 1994; 74: 3034–41.
29. Oeffinger K.C. Longitudinal risk-based health care for adult survivors of childhood cancer. Current. Probl. Cancer. 2003; 27: 143–67.
